Kim Henriksen Selected Research

balaglitazone

1/2017	Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes.
12/2016	Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy.
5/2011	Efficacy and safety of the PPARγ partial agonist balaglitazone compared with pioglitazone and placebo: a phase III, randomized, parallel-group study in patients with type 2 diabetes on stable insulin therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kim Henriksen Research Topics

Disease

25	Bone Resorption 12/2021 - 08/2003
14	Weight Loss (Weight Reduction) 12/2021 - 07/2014
14	Osteopetrosis 03/2021 - 11/2005
12	Insulin Resistance 12/2021 - 07/2013
12	Body Weight (Weight, Body) 01/2021 - 07/2013
11	Osteoporosis 09/2019 - 07/2004
9	Type 2 Diabetes Mellitus (MODY) 01/2020 - 08/2009
8	Obesity 12/2021 - 07/2013
7	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 01/2013
6	Dementia (Dementias) 10/2020 - 01/2015
5	Inflammation (Inflammations) 03/2019 - 12/2011
4	Osteoarthritis 09/2019 - 12/2011
4	Disease Progression 01/2017 - 08/2013
4	Fibrosis (Cirrhosis) 12/2016 - 07/2010
3	Rheumatic Diseases (Rheumatism) 01/2019 - 04/2011
3	Pain (Aches) 01/2019 - 12/2011
3	Liver Cirrhosis (Hepatic Cirrhosis) 12/2016 - 01/2012
2	Osteogenesis Imperfecta (Lobstein Disease) 01/2021 - 01/2019
2	Cognitive Dysfunction 10/2020 - 01/2017
2	Fatty Liver 01/2020 - 01/2017
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2020 - 01/2017
2	Brain Injuries (Brain Injury) 09/2019 - 11/2016
2	Necrosis 01/2019 - 01/2008
2	Hyperglycemia 01/2017 - 07/2014
2	Weight Gain 01/2017 - 05/2011
2	Hepatitis C 12/2016 - 01/2012
2	Glucose Intolerance 01/2016 - 07/2013
2	Hyperinsulinism (Hyperinsulinemia) 01/2016 - 07/2014
2	Hypertrophy 01/2016 - 01/2012
2	Wounds and Injuries (Trauma) 05/2013 - 03/2013
2	Neoplasms (Cancer) 03/2013 - 07/2006
2	Rheumatoid Arthritis 01/2012 - 04/2011
1	Nausea 12/2021
1	Vomiting 12/2021
1	Overweight 01/2021
1	Metabolic Diseases (Metabolic Disease) 01/2021

Drug/Important Bio-Agent (IBA)

28	Biomarkers (Surrogate Marker)IBA 01/2021 - 07/2006
20	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 03/2013
13	Islet Amyloid PolypeptideIBA 12/2021 - 09/2015
12	Calcitonin Receptors (Calcitonin Receptor)IBA 12/2021 - 09/2015
11	Insulin (Novolin)FDA Link 01/2020 - 08/2009
7	CalciumIBA 10/2016 - 09/2007
6	Peptides (Polypeptides)IBA 01/2021 - 11/2010
6	Collagen Type I (Type I Collagen)IBA 01/2021 - 07/2006
6	Matrix Metalloproteinases (MMPs)IBA 10/2020 - 08/2003
6	Proteins (Proteins, Gene)FDA Link 01/2020 - 11/2005
6	Pharmaceutical PreparationsIBA 01/2020 - 01/2010
6	salmon calcitonin (Calcimar)FDA LinkGeneric 01/2019 - 11/2010
5	KBP-042IBA 12/2021 - 07/2014
5	CollagenIBA 01/2021 - 08/2003
5	Peptide Hydrolases (Proteases)FDA Link 01/2019 - 02/2012
5	AcidsIBA 07/2014 - 09/2008
5	Chloride Channels (Chloride Channel)IBA 08/2013 - 07/2004
4	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2021 - 09/2015
4	KBP-088IBA 01/2020 - 01/2016
4	EpitopesIBA 01/2019 - 07/2006
4	Adenosine Triphosphatases (ATPase)IBA 09/2012 - 10/2007
4	Cathepsin KIBA 11/2005 - 08/2003
3	Liraglutide FDA Link 01/2021 - 11/2017
3	KBP-089IBA 01/2021 - 01/2017
3	Calcitonin (Calcitonin, Eel)FDA LinkGeneric 01/2021 - 01/2012
3	Blood Glucose (Blood Sugar)IBA 01/2020 - 08/2014
3	PPAR gammaIBA 03/2019 - 08/2009
3	N- (2(R)- 2- (hydroxamidocarbonylmethyl)- 4- methylpentanoyl)- L- tryptophan methylamideIBA 01/2019 - 06/2010
3	balaglitazoneIBA 01/2017 - 05/2011
3	ChloridesIBA 08/2013 - 09/2008
3	AntiportersIBA 04/2011 - 09/2008
3	Tartrate-Resistant Acid PhosphataseIBA 06/2010 - 07/2006
2	Hypoglycemic Agents (Hypoglycemics)IBA 12/2021 - 07/2014
2	IncretinsIBA 01/2021 - 09/2015
2	CholesterolIBA 01/2020 - 03/2019
2	Matrix Metalloproteinase InhibitorsIBA 01/2019 - 09/2012
2	Collagen Type II (Type II Collagen)IBA 01/2019 - 01/2019
2	collagen type I trimeric cross-linked peptideIBA 01/2019 - 07/2006
2	Oncostatin MIBA 01/2019 - 01/2008
2	Cysteine Proteinase InhibitorsIBA 01/2019 - 09/2012
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2018 - 01/2007
2	Anti-Obesity Agents (Antiobesity Drugs)IBA 11/2017 - 01/2016
2	CytokinesIBA 01/2017 - 08/2013
2	Pioglitazone (Actos)FDA Link 01/2017 - 05/2011
2	Complement C3 (C3 Complement)IBA 12/2016 - 01/2013
2	Biological ProductsIBA 09/2015 - 01/2007
2	LeptinIBA 09/2015 - 07/2013
2	Hormones (Hormone)IBA 07/2015 - 01/2007
2	beta-apocarotenoid-14',13'-dioxygenase (ADO)IBA 08/2013 - 09/2010
2	Carbon Tetrachloride (Tetrachloromethane)IBA 01/2013 - 01/2012
2	diphyllinIBA 09/2012 - 10/2007
2	Protons (Proton)IBA 04/2011 - 09/2008
2	Macrophage Colony-Stimulating FactorIBA 04/2007 - 01/2006
1	Glucagon-Like Peptide-1 ReceptorIBA 01/2021
1	Islet Amyloid Polypeptide ReceptorsIBA 01/2021
1	Glucagon (Glukagon)FDA Link 01/2021
1	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2021
1	Complement System Proteins (Complement)IBA 01/2021
1	Teriparatide (Parathar)FDA Link 01/2021
1	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 01/2021
1	Calcitonin Gene-Related PeptideIBA 01/2021
1	Amylin Receptor AgonistsIBA 01/2021

Therapy/Procedure

17	Therapeutics 03/2021 - 05/2011
2	Ovariectomy (Oophorectomy) 07/2013 - 07/2004